Studies have found that the addition of targeted therapy to preoperative neoadjuvant therapy can improve the prognosis of HER-2-positive breast cancer patients without significantly increasing cardiac toxicity (Petrelli et al., 2011; Schneeweiss et al., 2013). This evidence concerns the gene ERBB2 and breast carcinoma.